Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Definium Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Definium Therapeutics, Inc. is a mid-cap company with a market capitalization of $4.47B. It ranks number 1 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For DFTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -3.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, DFTX included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
| Metric | DFTX | Rank |
|---|---|---|
| Market Cap | $4.47B | 1/28 |
| P/B Ratio | 4.87x | 2/13 |
| EPS | $-3.00 | – |
| Book Value/Share | $6.84 | – |
| Metric | DFTX | Rank |
|---|---|---|
| ROE | -38.5% | 9/15 |
| ROA | -31.8% | 16/21 |
| ROIC | -23.8% | 15/18 |
| Metric | DFTX | Rank |
|---|---|---|
| Current Ratio | 6.95x | 2/25 |
| D/E Ratio | 0.21x | 14/16 |
| Financial Leverage | 1.21x | 14/16 |
| Interest Coverage | -60.9x | 19/21 |
| Working Capital | $935M | 1/25 |
| Metric | DFTX | Rank |
|---|---|---|
| Operating Cash Flow | -$168M | 26/27 |
| Metric | DFTX | Rank |
|---|---|---|
| Operating Income | -$228M | 23/26 |
| Net Income | -$354M | 19/21 |
| R&D Expense | $155M | 1/8 |
| Metric | DFTX | Rank |
|---|---|---|
| Shares Outstanding | 134M | – |
| Total Current Assets | $1.09B | 98.2% of assets |
| Cash & Short-term Investments | $655M | 58.9% of assets |
| Total Liabilities | $194M | 17.5% of assets |
| Short-term Debt | $150M | 13.5% of assets |
Companies classified under the same SEC industry code as Definium Therapeutics, Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $296M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.
Our AI scores Definium Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For DFTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -3.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Definium Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
30 issuers in our coverage, DFTX included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
